亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Large Format Engineered Cardiac Tissues (16050)

詳細技術說明
None
*Abstract

Large FormatEngineered Cardiac Tissues (16050)

   

     

Features and Benefits Summary

  • May provide higher efficiency cardiomyocyte production.

  • Mayprovide an implantable therapeutic option for enhancing cardiac repair andrecovery.

  • Possibleuse in drug toxicity screening.

 *This Technology is available for licensing, further development, or industrial partnering*

    

Market Opportunities

When the heart gets injured, heart cells are irreversibly lost and scar tissue forms at the site of the injury. This scar tissue is stiffer than normal cardiac tissue and cannot develop force to assist cardiac function. As a result, cardiac function deteriorates, leading to heart failure. This technology is able to reverse the decline in heart function by restoring new functional cardiac tissues onto damaged hearts. Current injected cell therapies under investigation suffer from cell death after delivery into patients. This engineered tissue technology was designed to improve cell survival and function because the graft is placed directly on the injured area of the heart in a formulation that promotes cell survival and coupling to the surrounding tissues, supporting better functional recovery. 

       

Technology   

Researchers from the University of Louisville andKyoto University have developed an engineered cardiac tissue technology intendedfor use in safe and effective cardiac repair. This technology is a large formatengineered cardiac tissue mesh produced in vitro from human pluripotent stemcells (iPSCs).  The large formatengineered mesh is scalable for human use and may grafted onto damaged orpreviously damaged cardiac tissue, promoting cardiac cell replacement and scarreduction.  This mesh may have a lowerrisk of rejection by the body due the human cell composition. This technologymay also be used as a product for drug screening and investigating cell to cellinteractions and drug to cell interactions.

     

Technology Status

  • IP Status: Provisional Patent Application
  • Development Status: In vivo implantations in rat model
  • Fields of Use Available: All

    

Researchers:

  • Dr. Bradley Keller
  • Dr. Takeichiro Nakane
  • Dr. Hidetoshi Masumoto
  • Dr. Yun Yamashita
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備